rapa-501 autologous t cells
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2020 (NCT04220190)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- T cellImmunity, desensitized
T cell immunity, desensitized
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04220190 | Phase 1 | Jul 1, 2020 | Hackensack University Medical Center, Harvard University, Rapa Therapeutics LLC |
| NCT06169176 | N/A | — | Hackensack University Medical Center, Harvard University, Rapa Therapeutics LLC |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hackensack University Medical Center | Academic/Hospital | 2 | 0 | 2 | 2020 |
| Harvard University | Academic/Hospital | 2 | 0 | 2 | 2020 |
| Rapa Therapeutics LLC | For profit | 2 | 2 | 2 | 2020 |
3 organizations
Page 1 / 1